YDES
YD Bio Ltd
Healthcare — Biotechnology
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
None
$7.81
+$0.39 (+5.26%)
Price History
52-Week Range
Sign in to add YDES to a watchlist or set price alerts.
Fundamentals
| Market Cap | $171.21M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.12 |
| Dividend Yield | - |
| Profit Margin | -276.58% |
| Revenue Growth | 95.60% |
| ROE | -42.69% |
| Debt/Equity | 0.34 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 32.8 |
| Beta | -0.18 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $25.00 |
| 52-Week Low | $2.14 |
| 50-Day Avg | $4.00 |
| 200-Day Avg | $9.74 |
| Avg Volume | 33.5K |
| Volume | 524 |
Performance Analysis
NEUTRALYDES presents a mixed picture with both positive and negative indicators.
~
Trading at 25% of its 52-week range.
~
RSI at 32.8 is in neutral territory.
+
Strong revenue growth of 95.6% year-over-year.
-
Operating at a loss with -276.6% margin.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:38 UTC
Back to Screener Export Report